DK1597280T3 - Fremstilling af monoklone antistoffer ved EBV-transformation af B-celler - Google Patents

Fremstilling af monoklone antistoffer ved EBV-transformation af B-celler

Info

Publication number
DK1597280T3
DK1597280T3 DK04714866.3T DK04714866T DK1597280T3 DK 1597280 T3 DK1597280 T3 DK 1597280T3 DK 04714866 T DK04714866 T DK 04714866T DK 1597280 T3 DK1597280 T3 DK 1597280T3
Authority
DK
Denmark
Prior art keywords
human
producing
memory
clone
cells
Prior art date
Application number
DK04714866.3T
Other languages
English (en)
Other versions
DK1597280T4 (da
Inventor
Antonio Lanzavecchia
Original Assignee
Inst Research In Biomedicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0325391A external-priority patent/GB0325391D0/en
Application filed by Inst Research In Biomedicine filed Critical Inst Research In Biomedicine
Priority claimed from PCT/IB2004/001071 external-priority patent/WO2004076677A2/en
Application granted granted Critical
Publication of DK1597280T3 publication Critical patent/DK1597280T3/da
Publication of DK1597280T4 publication Critical patent/DK1597280T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK04714866.3T 2003-02-26 2004-02-26 Fremstilling af monoklone antistoffer ved EBV-transformation af B-celler DK1597280T4 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0304363A GB2398783A (en) 2003-02-26 2003-02-26 A method for producing immortalised human B memory lymphocytes
GBGB0318431.4A GB0318431D0 (en) 2003-02-26 2003-08-06 Human monoclonal antibodies
US51666503P 2003-10-30 2003-10-30
GB0325391A GB0325391D0 (en) 2003-02-26 2003-10-30 Human monoclonal antibodies
PCT/IB2004/001071 WO2004076677A2 (en) 2003-02-26 2004-02-26 Monoclonal antibody production by ebv transformation of b cells

Publications (2)

Publication Number Publication Date
DK1597280T3 true DK1597280T3 (da) 2012-08-13
DK1597280T4 DK1597280T4 (da) 2016-10-03

Family

ID=9953683

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04714866.3T DK1597280T4 (da) 2003-02-26 2004-02-26 Fremstilling af monoklone antistoffer ved EBV-transformation af B-celler

Country Status (10)

Country Link
US (5) US8071371B2 (da)
EP (1) EP2298804A3 (da)
AT (1) ATE556091T2 (da)
DK (1) DK1597280T4 (da)
ES (1) ES2389930T5 (da)
GB (2) GB2398783A (da)
HU (1) HUE015415T5 (da)
IL (1) IL183370A (da)
PT (1) PT1597280E (da)
SG (1) SG181999A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1627563A1 (en) 2004-08-10 2006-02-22 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for producing a stabilized cell of interest
EP1954811B1 (en) 2005-11-17 2011-06-08 TET Systems GmbH & Co. KG Inducible expression systems
USRE49583E1 (en) 2005-11-17 2023-07-18 Tet Systems Gmbh & Co. Kg Inducible expression systems
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
EP2540820B1 (en) 2005-12-09 2018-01-10 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for influencing the stability of antibody producing cells
EP1974020B1 (en) * 2005-12-16 2011-06-15 Ribovax Biotechnologies SA Methods for obtaining immortalized antibody secreting cells
EP2185718B1 (en) 2007-08-03 2017-10-04 MUSC Foundation For Research Development Human monoclonal antibodies and methods for producing the same
CA2768207C (en) 2009-07-15 2019-12-03 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
EP3037435B1 (en) 2009-11-17 2019-08-07 MUSC Foundation for Research Development Human monoclonal antibodies to human nucleolin
AU2010334809C1 (en) 2009-12-23 2015-02-26 Agenus Inc. Binding members for human cytomegalovirus
AU2011238922A1 (en) * 2010-04-09 2012-11-01 Duke University Method for the generation of monoclonal antibodies derived from human B cells
RU2585153C2 (ru) 2010-12-02 2016-05-27 Аимм Терапьютикс Б.В. Средства и способы получения высокоаффинных антител
CN103380145B (zh) * 2010-12-17 2016-10-12 生物控股有限公司 人类抗-sod1抗体
WO2014093786A1 (en) * 2012-12-14 2014-06-19 Abbvie, Inc. Methods for increasing the efficiency of hybridoma generation
CN103232971A (zh) * 2013-04-11 2013-08-07 哈尔滨体育学院 一种优秀冰雪运动员eb病毒转化b淋巴细胞的方法
BR112016017597A2 (pt) 2014-01-31 2017-08-08 Aimm Therapeutics Bv Métodos para produzir uma célula b, para selecionar pelo menos uma célula b, para produzir anticorpos específicos para um antígeno de interesse e para identificar pelo menos uma mutação na sequência de aminoácido da cadeia pesada e/ou cadeia leve de um anticorpo
MA48852A (fr) 2015-05-13 2020-04-01 Univ Pennsylvania Expression médiée par aav d'anticorps anti-grippaux et leurs procédés d'utilisation
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
US10222369B2 (en) * 2016-05-17 2019-03-05 Chimera Bioengineering, Inc. Methods for making novel antigen binding domains
WO2018175390A1 (en) * 2017-03-20 2018-09-27 Washington University Cells and methods of uses and making the same
WO2018237010A2 (en) 2017-06-20 2018-12-27 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College VACCINE COMPOSITIONS AGAINST STREPTOCOCCUS AND THEIR METHODS OF USE
IL260412B (en) * 2018-07-04 2022-06-01 The Israel Institute Of Biological Res Iibr Antibodies against Francisella tolerensis
CN111647566A (zh) * 2019-07-10 2020-09-11 广州医科大学附属第一医院 一种高滴度eb病毒的制备方法、eb病毒永生化记忆性b细胞的方法与应用
CN111690056B (zh) * 2020-04-30 2021-12-21 清华大学 一种中和eb病毒的单克隆抗体及其应用
WO2022011160A2 (en) * 2020-07-08 2022-01-13 The Brigham And Women's Hospital, Inc. Severe acute respiratory syndrome coronavirus 2 (sars cov-2) peptide epitopes
NL2026043B1 (en) 2020-07-10 2022-03-15 Leyden Laboratories B V Methods for identifying coronavirus cross-reacting antibodies
CN113321728A (zh) * 2021-05-25 2021-08-31 安徽省立医院(中国科学技术大学附属第一医院) 新型人源性单克隆中和性抗体xg-81与xg-83的制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464465A (en) * 1982-04-05 1984-08-07 Genetic Systems Corporation Cell-driven viral transfer in eukaryotes
US5106738A (en) * 1984-01-31 1992-04-21 Akzo Nv Tumor specific monoclonal antibodies
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4997764A (en) * 1987-04-23 1991-03-05 New York University Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors
WO1989000607A1 (en) 1987-07-09 1989-01-26 The United States Of America, As Represented By Th Preparation of human monoclonal antibodies of selected specificity and isotypes
JPH03503960A (ja) 1988-12-19 1991-09-05 ニューヨーク　ユニバーシィティ ヒトｂ‐リンパ球の形質転換方法
EP0434879A1 (en) 1989-12-14 1991-07-03 Schering-Plough Method of making factor dependent human B cell lines
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US6685942B1 (en) * 1993-12-10 2004-02-03 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
EP0619323A1 (en) 1993-04-09 1994-10-12 Schering-Plough Human monoclonal antibodies and processes and materials for making such antibodies
US5874085A (en) * 1993-11-10 1999-02-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Vaccine for enhanced production of IgA antibodies
JPH09507055A (ja) * 1993-11-10 1997-07-15 ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン Ｂリンパ球による抗体放出を刺激するための組成物および方法
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
ATE420171T1 (de) 1994-07-15 2009-01-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE194291T1 (de) * 1995-09-18 2000-07-15 Intracel Corp Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
AU3167197A (en) 1996-06-28 1998-01-21 Rockdelta A/S A sound absorbing and/or reducing wall or baffle
DE19646880A1 (de) 1996-11-13 1998-05-14 Hoechst Schering Agrevo Gmbh Endosulfan-Mikrokapseldispersion
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
WO1998057993A1 (en) 1997-06-19 1998-12-23 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
GB2328071A (en) 1997-07-31 1999-02-10 Hi Tech Developments Limited Apparatus for protecting and/or repairing an optical surface
FR2817875B1 (fr) * 2000-12-07 2005-03-18 Technopharm Procede de preparation d'un anticorps monoclonal humain, de fragments de celui-ci ou d'anticorps comprenant de tels fragments, les anticorps ainsi obtenus et leur utilisation
CA2480775C (en) 2002-04-04 2016-05-31 Coley Pharmaceutical Gmbh Immunostimulatory g,u-containing oligoribonucleotides
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
EP1974020B1 (en) 2005-12-16 2011-06-15 Ribovax Biotechnologies SA Methods for obtaining immortalized antibody secreting cells
WO2007087576A2 (en) * 2006-01-24 2007-08-02 The Uab Research Foundation Compositions and methods for the identification and treatment of immune-mediated inflammatory diseases

Also Published As

Publication number Publication date
US20140004123A1 (en) 2014-01-02
US9290786B2 (en) 2016-03-22
DK1597280T4 (da) 2016-10-03
EP2298804A3 (en) 2011-08-24
US20100021470A1 (en) 2010-01-28
IL183370A (en) 2015-05-31
GB2398783A (en) 2004-09-01
GB0318431D0 (en) 2003-09-10
IL183370A0 (en) 2011-08-01
GB0304363D0 (en) 2003-04-02
US20120027768A1 (en) 2012-02-02
US8071371B2 (en) 2011-12-06
ES2389930T5 (es) 2017-02-23
SG181999A1 (en) 2012-07-30
US20160160258A1 (en) 2016-06-09
PT1597280E (pt) 2012-08-03
HUE015415T5 (en) 2017-04-28
EP2298804A2 (en) 2011-03-23
ES2389930T3 (es) 2012-11-05
ATE556091T2 (de) 2012-05-15
US20180327800A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
DK1597280T3 (da) Fremstilling af monoklone antistoffer ved EBV-transformation af B-celler
WO2004076677A3 (en) Monoclonal antibody production by ebv transformation of b cells
ES2173237T3 (es) Procedimiento de fabricacion de anticuerpos monoclonales humanos y su uso.
DK1167537T3 (da) Fremgangsmåde til fremstilling af et monoklonalt antistof
WO2005072112A3 (en) Methods for producing and identifying multispecific antibodies
DE69230146D1 (de) Monoklonale antikörper gegen putative hcv-e2/ns1-proteine und verfahren zu ihrer verwendung
KR880006357A (ko) 인터류킨-i에 대한 항체
DK1414858T3 (da) Kamelid-enkeltkæde-VHH-antistoffer, fremgangsmåde til fremstilling heraf i et pattedyr samt anvendelser heraf
GB0312481D0 (en) Antibodies
CA2268143A1 (en) Production of a multimeric protein by cell fusion method
EP2186884A3 (en) HCV-anti-core monoclonal antibody
EP0176355A3 (en) Antigen-independent immunoassay system
RU2005131842A (ru) Моноклональное антитело и продуцирующая его гибридома
EP1536004A4 (en) METHOD FOR PROMOTING HOMOLOGOUS RECOMBINATION OF SOMATIC CELLS AND METHOD FOR CONSTRUCTING A SPECIFIC ANTIBODY
ATE161581T1 (de) Monoklonale antikörper gegen humane pankreas- inselzellen
EP1645183A4 (en) PROCESS FOR THE MANUFACTURE OF IMMUNOMETER CELLS OF HUMAN ORIGIN
DK1141026T3 (da) Sammensætninger og fremgangsmåder til frembringelse af monoklonale antistoffer repræsentative for en specifik celletype
ATE288485T1 (de) Monoklonaler antikörper 4g8b4b12 gegen humanes flt3/flk2
AU2003283240A1 (en) Antibody for isolating and/or identifying mesenchymal stem cells and method for isolating and/or identifying mesenchymal stem cells
ATE116004T1 (de) Antikörper gegen menschliches sperma, ihre herstellung und anwendung.
PL362164A1 (en) Monoclone antibody, method of receiving monoclone antibodies, method of production of epitope, method of determination of quantity and strength of inactivated fiv, hybrid cell line and method of its production
DK1463816T3 (da) Fremgangsmåde til kontrolleret induktion af somatiske mutationer og anvendelse heraf inden for proteomik
WO2005003379A3 (fr) Procede automatise de criblage a grande echelle de cellules secretant des anticorps monoclonaux
JPS6429400A (en) Monoclonal antibody
DK1161522T3 (da) Fremgangsmåde til isolering af CD8+-celler og beslægtede hybridomaceller, antistoffer og polypeptider